Encell Presents EN001 Clinical Results at International Society for Stem Cell Research

Encell, a company specializing in advanced biopharmaceutical CDMO (Contract Development and Manufacturing Organization) and new drug development, participated in the 2025 International Society for Stem Cell Research (ISSCR) Annual Meeting held in Hong Kong from June 11 to June 14 (local time), where it presented the results of the Phase 1 clinical trial of its new drug pipeline EN001.

ISSCR is one of the world's largest societies related to stem cell research, with approximately 4,000 participants from over 70 countries attending its annual meeting each year. Encell participated in this conference for the first time and presented the results of the Phase 1 clinical trial of its new drug pipeline EN001 on June 13.

Encell announced the long-term follow-up results of a single-dose Phase 1 clinical trial of EN001 in patients with CMT1A (Charcot-Marie-Tooth disease type 1A), which was met with a strong positive response locally. No adverse effects were observed up to 48 weeks, demonstrating the safety of EN001. In addition, exploratory efficacy assessments of EN001 confirmed that therapeutic efficacy was maintained even in the high-dose group.

Notably, ISSCR introduced a one-on-one partnering system this year, allowing Encell to conduct business partnering with leading global biotech companies in the field of stem cell therapeutics. Through active promotion of the company, including EN001, which recently received orphan drug designation from the FDA (U.S. Food and Drug Administration), Encell also sought opportunities for global CDMO contracts and license-out (technology transfer).

A representative from Encell stated, "At this conference, we were able to confirm the high level of local interest in the clinical results of EN001, and we expect that the possibility of license-out will increase as additional clinical trials continue." The representative added, "We plan to actively promote the company at major domestic and international conferences to showcase our global-level technological capabilities and future growth potential."